The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.

• Status: Completed
• Trial end date: 2020-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The COVID-19 pandemic is of grave concern due its impact on human health and on the economy. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, anti-oxidant properties, and various aspects of the SARS-CoV-2 infection mechanism are potential targets for propolis compounds. Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways; in addition, antiviral activity has been proven in vitro and in vivo. This is a pilot randomized study that aims to assess the impact of using Brazilian green propolis extract against the deleterious effects of the new coronavirus.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: D'Or Institute for Research and Education
• Collaborator: Hospital Sao Rafael
• Treatments: Propolis

Criteria

Inclusion Criteria:

• Hospitalized patients;

• Positive RT-PCR for SARS-CoV-2;

• 18 Years and older.

Exclusion Criteria:

• Pregnant women;

• People with active cancer;

• Patients undergoing transplantation of solid organs or bone marrow or who use immunosuppressive medications;

• HIV carriers;

• Allergy to propolis or any of its components;

• Bacterial infection at randomization;

• Sepsis or septic shock before randomization;

• Patients unable to use medication orally or via nasoenteral tube;

• Patients with severe chronic liver disease (Child B or C);

• Patients with advanced heart failure;